BioDelivery Sciences readies BEMA for application; pSivida's Iluvien gets Spanish agency nod;

> AstraZeneca ($AZN) has signed up with U.K.-based materials development company Ceram to develop extended-release versions of AstraZeneca compounds. Ceram's controlled-release technologies use glass, ceramics and powder to deliver individual drugs or drug combinations over extended periods. Press release

> BioDelivery Sciences International ($BDSI) has completed the safety study of its BioErodible MucoAdhesive (BEMA) formulation of buprenorphine and naloxone, known as BNX. According to the company, it's still on track for a midyear new drug application submission. Press release

> Omeros finished its Phase III trial for OMS302, which eases the pain and discomfort of cataract and other lens-replacement surgery. Press release

> Velocity Pharmaceutical Development and EuMederis Pharmaceuticals have joined forces to improve the overall handling of peptides, including their delivery. Report

> The Spanish Agency of Drugs granted marketing authorization to pSivida ($PSDV), a sustained-release drug company, for Iluvien, designed to treat vision impairment associated with chronic diabetic macular edema. Report

> The FDA issued a complete response letter for the NDA of Rytary extended-release capsules by Impax Laboratories ($IPXL). The agency stated that it would require a re-inspection of the company's facility before the NDA can be approved. Press release